Exhale

The official blog of the Lung Institute.

Lung Institute White Paper Reveals Evidence of Pulmonary Function Improvement from Cellular Treatment Therapy

21 Jan 2016
| Under Press | Posted by
| 6 Comments
Lung Institute White Paper

A new white paper released by the Lung Institute shows an increase of 10 percent or more in pulmonary function for 48 percent of patients tested after receiving cellular therapy for COPD, with an overall average increase of 16 percent.

TAMPA, Fla. – January 26, 2016: Lung Institute doctor Jack Coleman, Jr., M.D. recently released a white paper showing evidence that cellular therapy for lung diseases improves most patients’ quality of life scores and, in some cases, pulmonary function. The paper outlines a study that was conducted following 100 patients who received cellular therapy for chronic obstructive pulmonary disease (COPD).

“COPD is currently the third leading cause of death in the United States, and we’re giving our patients an alternative option that doesn’t just mask the symptoms.”

COPD and Cellular Therapy“Although research on the use of autologous cells is still in its early stages, it has shown substantive progress in treating patients with few, if any, adverse effects,” Dr. Coleman stated. “COPD is currently the third leading cause of death in the United States, and we’re giving our patients an alternative option that doesn’t just mask the symptoms.”

Coleman’s white paper summarizes the results of a study where approximately 100 patients with lung diseases were treated using cellular therapy. Three months after treatment, 84 percent of patients reported an improved quality of life. The average improvement was 35 percent. Additionally, 25 of the patients in this study group were tested for pulmonary function. 48 percent of those 25 patients saw an increase in pulmonary function of over 10 percent, with the average rate of improvement at 16 percent. This sampling of patients represents one of the largest study groups tested in regard to how cells affect those with lung diseases.

Lung diseases are degenerative, meaning pulmonary function is expected to decline, making an increase in pulmonary function even more noteworthy. Advancements such as this are why the Vatican hosts an annual conference on regenerative medicine and why the White House recently passed a bill approving cellular research funding.

Supporters like the White House and Vatican are helping increase awareness as to all of the benefits of regenerative cellular therapy. In an article published on ChristianNewsWire, U.S. Rep. Chris Smith recently stated, “It remains one of the best kept secrets in America that umbilical cord blood cells and adult cells in general are curing people of a myriad of terrible conditions and diseases in adults as well as children.”

About the Lung Institute 

The Lung Institute, founded in 2013, is a leading medical provider of regenerative cellular therapy for lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and interstitial lung disease in the United States. Based in Tampa, Fla., the Lung Institute currently has clinics in Nashville, Tenn., Scottsdale, Ariz., and Pittsburgh, Pa., with plans to open three new locations in 2016. To date the organization has treated over 1,500 patients, helping them breathe easier in their fight against lung disease. For more information, please visit www.lunginstitute.com or call (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.